Abstract
Disruptions in the balance of excitation-inhibition (E/I) ratios are implicated as a common pathway in Autism Spectrum Disorder (ASD). This implication may have important consequences for treatment developments as several existing agents can shift E/I balance. Bumetanide is an E/I-shifting candidate due to its putative actions on chloride homeostasis and GABAergic transmission. In this part of the symposium, we present effects of bumetanide on cognitive measures as part of the forthcoming results of the BAMBI trial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
